Valuation: Apnimed, Inc.

Market Cap 589M 525M 480M 438M 825M 55.71B 847M 5.77B 2.31B 29.5B 2.21B 2.17B 93.1B P/E 2026 *
3.99x
P/E 2027 * -3.4x
Enterprise Value 589M 525M 480M 438M 825M 55.71B 847M 5.77B 2.31B 29.5B 2.21B 2.17B 93.1B EV / Sales 2026 *
6.49x
EV / Sales 2027 * 26.3x
Free-Float
64.39%
Yield 2026 *
-
Yield 2027 * -
1 day-7.45%
1 week-18.34%
Current month-13.66%
1 month-34.90%
3 months-46.59%
1 week 13.88
Extreme 13.88
16.99
1 month 13.88
Extreme 13.88
20
Current year 13.88
Extreme 13.88
35.29
1 year 13.88
Extreme 13.88
35.29
3 years 13.88
Extreme 13.88
35.29
5 years 13.88
Extreme 13.88
35.29
10 years 13.88
Extreme 13.88
35.29
Manager TitleAgeSince
Corporate Officer/Principal 42 01/06/2018
Chief Executive Officer 50 02/06/2026
Chief Tech/Sci/R&D Officer - 04/03/2021
Director TitleAgeSince
Chairman 73 01/01/2018
Director/Board Member 77 01/06/2017
Director/Board Member 46 01/01/2023
Date Insider Type Main position Quantity % Market Cap. Importance
8/3/26 A Issuer sale

Director

-281,688 0.7072%
8/3/26 A Issuer sale

Chairperson

-1,499,492 3.7648%
8/3/26 A Issuer sale

Chief Executive Officer

-2,738,644 6.8760%
Change 5-day change 1-year change 3-year change Capi.($)
-7.45%-18.34% - - 589M
+3.80%+8.10%+63.78%+77.70% 69.4B
-1.35%-0.27%+9.17%+74.32% 57.24B
-2.33%+1.74%+23.29%+97.77% 57.62B
+0.41%-3.70%+26.06%+34.32% 43.65B
+2.51%+4.22%+20.49%+110.71% 44.03B
-11.04%-6.63%+199.38%+701.67% 38.08B
+7.50%+13.58%+29.07%+64.46% 36.31B
-3.01%-9.97%+88.59%+75.92% 32.61B
-2.18%+7.06%+36.06%-4.95% 25.47B
Average -1.15%+0.68%+55.10%+136.88% 40.5B
Weighted average by Cap. -0.13%+3.09%+51.40%+131.20%

Financials

2026 *2027 *
Net sales 90.85M 80.96M 74.05M 67.44M 127M 8.59B 131M 890M 356M 4.55B 341M 334M 14.35B 22.44M 19.99M 18.29M 16.65M 31.39M 2.12B 32.24M 220M 87.85M 1.12B 84.22M 82.41M 3.54B
Net income 144M 128M 118M 107M 202M 13.62B 207M 1.41B 565M 7.22B 541M 530M 22.77B -151M -135M -123M -112M -211M -14.28B -217M -1.48B -592M -7.56B -567M -555M -23.87B
Net Debt - -
Projected Income Statement - Annual - Apnimed, Inc.
Logo Apnimed, Inc.
Apnimed, Inc. is a late-stage clinical pharmaceutical company dedicated to the discovery, development and commercialization of novel oral therapies that address the neurobiology of sleep-related breathing diseases. The Company's clinical product candidate, AD109 (Oxnimbi), is an investigational, fixed-dose, anti-apneic neuromuscular modulator, combining a novel anti-muscarinic and a selective norepinephrine reuptake inhibitor (NRI) for the treatment of obstructive sleep apnea (OSA). Oxnimbi is designed to target the neuromuscular defect of OSA by improving upper airway muscle activity to help maintain airway patency and prevent airway collapse during sleep.
Employees
81
Date Price Change Volume
05/11/26 $14.16 -7.45% 448,294
04/11/26 $15.30 +1.59% 604,510
03/11/26 $15.06 -2.21% 575,783
02/11/26 $15.40 -6.10% 530,945
30/10/26 $16.40 -5.42% 466,517
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
14.16USD
Average target price
50.33USD
Spread / Average Target
+255.46%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Apnimed, Inc.
  1. Stock Market
  2. Stocks
  3. APMD Stock